Compare Incyte Corporation (INCY) vs T-Rex 2X Inverse MSTR Daily Target ETF (MSTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs T-Rex 2X Inverse MSTR Daily Target ETF — how do they compare? Incyte Corporation trades at $112.77 (market cap $22.85B), while T-Rex 2X Inverse MSTR Daily Target ETF trades at $2.62 (market cap $94.46M). The key difference: Incyte Corporation is far larger — about 241.9× T-Rex 2X Inverse MSTR Daily Target ETF's market cap, and Incyte Corporation is trading nearer its 52-week high, T-Rex 2X Inverse MSTR Daily Target ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and T-Rex 2X Inverse MSTR Daily Target ETF for 8 Days on average.
| INCY | MSTZ | |
|---|---|---|
Market Cap | $22.85B | $94.46M |
Volume | 1,927,029 | 104,717,733 |
Sector | Health | Leveraged / Inverse |
52-Week High | $129.93 | $27.92 |
52-Week Low | $83.80 | $2.29 |
Typical Hold Time | 33 Days | 8 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.61, up 0.15% on the day, with a mixed technical signal leaning bearish. The company reported strong 2025 results with revenue of $5.14B and net income of $1.29B, and recent earnings beats in Q1 and Q2 2026. Key developments include FDA approval for Atebrioz and a strategic focus on post-JAKAFI growth targeting $4B in non-JAKAFI sales by 2029.
The outlook is cautiously optimistic, supported by robust profitability and pipeline progress, but tempered by near-term earnings pressure and technical weakness. Risks include JAKAFI's patent expiration after 2029 and competitive threats. Analysts maintain a Buy consensus with a $132.43 price target, implying significant upside from current levels.
MSTZ trades at $2.58, down 3.01% with bearish technical signals from moving averages. The stock shows mixed momentum with neutral oscillators but negative moving average alignment. Key support sits at $2 with resistance at $3. Recent ETF coverage highlights the stock's inclusion in leveraged/inverse ETF discussions, though specific company fundamentals remain limited in available data.
Outlook remains cautious given technical weakness and limited fundamental visibility. The primary opportunity lies in potential technical rebounds from support levels, while risks include continued bearish momentum and lack of clear fundamental catalysts. Investors should await clearer financial metrics and earnings guidance for directional conviction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About T-Rex 2X Inverse MSTR Daily Target ETF
MSTZ is a leveraged ETF that seeks daily investment results corresponding to 200% of the inverse (opposite) of the daily performance of the MicroStrategy Incorporated (MSTR) stock. It is designed as a tactical tool for experienced traders to take a bearish position on MSTR, a company known for its large Bitcoin holdings. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from its stated daily objective.
Read more on MSTZ →
